Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

28 October 2022

Mereo BioPharma Group plc today announced it has entered into a cooperation agreement (the “Agreement”) with Rubric Capital Management LP (“Rubric”), its largest shareholder. Pursuant to the Agreement, four new directors – Dr. Annalisa Jenkins, Dr. Daniel Shames, Mr. Marc Yoskowitz and Mr. Justin Roberts – will be appointed to the Company’s Board of Directors as soon as practicable. Concurrent with these appointments taking effect, directors Dr. Peter Fellner, Dr. Brian Schwartz, Dr. Abdul Mullick and Ms. Anne Hyland will resign from the Board.

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

24 October 2022

Mereo BioPharma today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD). The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for alvelestat from the FDA announced on October 17, 2022.

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

21 October 2022

Mereo BioPharma to Present at Two Upcoming Investor Conferences

17 November 2021

Mereo to Participate in Fireside Chat at Jefferies Healthcare Conference: November 17, 2021 at 10:00am GMT